The panelists provide their perspective on best practices for keeping up with the rapidly evolving RET fusion landscape and unmet needs to be addressed by future RET-targeted therapies beyond lung cancer.
The FDA has granted fast track designation to naporafenib plus trametinib for use as a potential therapeutic option in adult patients with unresectable or metastatic melanoma with an NRAS mutation who progressed on or are intolerant to a PD-1/PD-L1–based regimen.
The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.
Expert oncologist Premal Thaker, MD, MS, reviews the current treatment landscape for recurrent low-grade serous ovarian cancer and considers the respective roles of various targeted agents in this setting.